Wellmarker Bio, a company committed to discovering and developing first-in-class anti-cancer drugs with predictive biomarkers, presented preclinical data for WM-A1 at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021. WM-A1 is a novel therapeutic antibody for NSCLC patients with low and negative PD-L1 tumors and so far demonstrated high immunotherapeutic effect in a PBMC humanized model. 
Wellmarker Bio identified a novel protein A which is highly expressed in NSCLC patients with low and negative PD-L1. Same results were verified in the TCGA (The Cancer Genome Atlas) data  and to the best of their knowledge, WMBIO is the first and the only biotechnology company to develop WM-A1 that inhibits the protein A and protein B, inducing the cancer cell death for the NSCLC patients with low/negative PD-L1.

According to the company, predictive biomarker-based novel therapeutic antibody WM-A1 is expected to get a limelight as a drug that could overcome the resistance of current therapies. 
Details of the abstract can be found as follows.


Pipeline: WM-A1 
Title: 1216 - New therapeutic antibody ("WM-A1") for treatment of low or no PD-L1 NSCLC patients
Link: https://www.abstractsonline.com/pp8/#!/9325/presentation/2012